Previous research results have shown that ERA, PDE5i, sGC agonists, prostacyclin analogues and prostacyclin receptor agonists can improve 6MWD, mPAP, PVR, NT-proBNP concentration, clinical deterioration time and WHO-FC to varying degrees in the treatment of PAH (16, 17). This evidence concerns the gene SGCB and pulmonary arterial hypertension.